XNAS
ICLR
Market cap12bUSD
Sep 17, Last price
169.68USD
1D
-2.45%
1Q
16.22%
Jan 2017
125.64%
Name
ICON PLC
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Related entities
Subsidiaries (6)
ICON Clinical Research Limited
ICON Investments (UK) Limited
ICON INVESTMENTS SIX DESIGNATED ACTIVITY COMPANY
DOCS Resourcing Ltd
ICON CLINICAL RESEARCH INDIA PRIVATE LIMITED
ICON Global Treasury Limited
Key people
Ciaran Murray
Non-Executive Independent Chairman of the Board · since 2021
Chief Financial Officer · since 2024
Barry Balfe
Chief Executive Officer, Chief Operating Officer · since 2025
Diarmaid Cunningham
Chief Administrative Officer, General Counsel, Company Secretary · since 2022
Ronan Murphy
Lead Independent Director · since 2019
Stephen Cutler
Chief Executive Officer, Director · since 2017
John Climax
Independent Director · since 2010
Independent Director · since 2021
Eugene Mccague
Independent Director · since 2017
Independent Director · since 2019
Independent Director · since 2024
Headquarters & legal address
South County Business park
Leopardstown
Dublin, D D18X5R3
IE
Leopardstown
Dublin, D D18X5R3
IE
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||